GILDGilead SciencesNot started yet
Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer
NSCLC · Non Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 80 (planned)
- Started
- Nov 2026
- Main results expected
- May 2029
- Fully finished
- May 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
Measured over: From enrollment until 30 days after last dose of study drug
Overall Response Rate (ORR)
Measured over: Enrollment until approximately 80 days since last dose of study drug
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07806773 · record last updated 2026-09-16 · checked 2026-11-09 15:47 UTC